628-12-6

Basic information

• Product Name: 2-METHOXYETHYL CHLOROFORMATE
• Synonyms: 2-Methoxyethyl chloroformate, tech. 85%;2-methoxyethyl carbonochloridate;chlorocarbonic acid 2-methoxyethyl ester;(2-Methoxyethoxy)carbonyl chloride;(Chloro)(2-methoxyethoxy)methanone;Chloroformic Acid 2-Methoxyethyl Ester Ethylene Glycol Monomethyl Ether Chloroformate;2-METHOXYETHYL CHLOROFORMATE;CHLOROFORMIC ACID 2-METHOXYETHYL ESTER
• CAS NO: 628-12-6
• Molecular Formula: C₄H₇ClO₃
• Molecular Weight: 138.55
• EINECS: 211-026-9
• Product Categories: CHLOROFORMATES;Acid Halides;Carbonyl Compounds;Organic Building Blocks;Acid Halides;Building Blocks;Carbonyl Compounds;Chemical Synthesis;Organic Building Blocks
• Mol File: 628-12-6.mol

Chemical Properties

• Boiling Point: 157-158 °C(lit.)
• Flash Point: 138 °F
• Appearance: /
• Density: 1.192 g/mL at 25 °C(lit.)
• Vapor Pressure: 4.71mmHg at 25°C
• Refractive Index: n20/D 1.4200(lit.)
• Storage Temp.: 2-8°C
• Solubility: Soluble in most organic solvents.
• Sensitive: Moisture Sensitive
• CAS DataBase Reference: 2-METHOXYETHYL CHLOROFORMATE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-METHOXYETHYL CHLOROFORMATE(628-12-6)
• EPA Substance Registry System: 2-METHOXYETHYL CHLOROFORMATE(628-12-6)

Safety Data

• Hazard Codes: C
• Statements: 34
• Safety Statements: 26-36/37/39-45
• RIDADR: UN 2920 8/PG 2
• WGK Germany: 3
• F: 10-21
• HazardClass: 6.1
• PackingGroup: II
• Hazardous Substances Data: 628-12-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-METHOXYETHYL CHLOROFORMATE is used as a reactant for the preparation of N-bridged bicyclic sulfonamides, which act as inhibitors of γ-secretase. This application is significant in the development of potential treatments for Alzheimer's disease.
Used in Chemical Synthesis:
2-METHOXYETHYL CHLOROFORMATE is used as a reactant for the preparation of dimethoxyethyl azodicarboxylate via amidation/oxidation. 2-METHOXYETHYL CHLOROFORMATE is then applied to the Mitsunobu reaction, a widely used method for the inversion of stereochemistry and the formation of new carbon-heteroatom bonds.
Used in Organic Chemistry:
2-METHOXYETHYL CHLOROFORMATE is employed in the regioselective, stereoselective, and kinetically-controlled nickel-catalyzed cyanoesterification of allenes, chloroformates, and TMSCN. This reaction provides a route to access various synthetically valuable compounds.
Used in Medicinal Chemistry:
2-METHOXYETHYL CHLOROFORMATE is used as a reactant for the preparation of amino carboxamidobenzothiazoles, which serve as Lck inhibitors. These compounds have potential applications in the treatment of autoimmune diseases and cancer.
Used in Asymmetric Synthesis:
2-METHOXYETHYL CHLOROFORMATE is utilized in the preparation of nonracemic spirooxindoles using a stereoselective three-component coupling reaction as the key step. This method allows for the synthesis of chiral compounds with potential applications in the pharmaceutical industry.
Used in Alternative Reagent Development:
2-METHOXYETHYL CHLOROFORMATE was used to produce di-2-dimethoxyethyl hydrazine carboxylate, which serves as an alternative reagent for the Mitsunobu reaction. This development expands the scope of the Mitsunobu reaction and provides a new synthetic route for various applications.

InChI:InChI=1/C4H7ClO3/c1-7-2-3-8-4(5)6/h2-3H2,1H3

Upstream product

• 75-44-5 phosgene 
• 109-86-4 2-methoxy-ethanol 
• 32315-10-9 bis(trichloromethyl) carbonate 

Downstream Products

• 1616-88-2 2-methoxyethyl carbamate 
• 22575-95-7 bis-(2-methoxy-ethoxycarbonyl)-peroxide 
• 94257-33-7 7-(2-methoxy-ethoxycarbonylamino)-3-phenyl-coumarin 
• 5555-83-9 N-Benzyl-N-benzyloxy-carbamidsaeure-(2-methoxy-ethylester) 
• 56456-32-7 3-Amino-2,4,6-triiodo-5-[(2-methoxy-ethoxycarbonylamino)-methyl]-benzoic acid 
• 37654-03-8 4-(((2-methoxyethoxy)carbonyl)amino)benzoic acid 
• 98050-90-9 2,4-Dimethyl-6-(2-nitro-phenyl)-6H-pyrimidine-1,5-dicarboxylic acid 5-cyclopropylmethyl ester 1-(2-methoxy-ethyl) ester 
• 15258-27-2 N-Benzyloxy-N-(3-phenyl-propyl)-carbamidsaeure-(2-methoxy-ethylester) 
• 209746-65-6 Carbonic acid (2R,3S,4S,5R,6S)-6-[3-allyloxy-2-(3-benzofuran-5-yl-propionyl)-5-methyl-phenoxy]-3,4,5-trihydroxy-tetrahydro-pyran-2-ylmethyl ester 2-methoxy-ethyl ester 
• 357413-57-1 (4'-methoxy-biphenyl-4-sulfonylamino)-[1-(2-methoxy-ethoxycarbonyl)-piperidin-4-yl]-acetic acid methyl ester 
• 936633-35-1 4-{2-tert-butoxycarbonylmethyl-3-[4-(di-tert-butoxy-phosphorylmethyl)-phenyl]-propionylamino}-4-[2-carbamoyl-1-(3-naphthalen-1-yl-propylcarbamoyl)-ethylcarbamoyl]-piperidine-1-carboxylic acid 2-methoxy-ethyl ester 

Relevant articles and documents

Synthesis and in vitro evaluation of S-acyl-3-thiopropyl prodrugs of Foscarnet

A new enzyme-labile group called S-acyl-3-thiopropyl group (SATP) has been synthesized from allylic esters of phosphonate. After demonstration of the enzyme-labile character of the SATP in cellular extracts, it has been introduced onto the phosphonate moiety of PFA (Foscarnet) to obtain potential lipophilic prodrugs. To ponder the lipophilicity of the triesters of PFA, esters of monomethylether of polyethyleneglycols and of thioglycerol were introduced on the PFA carboxylate moiety. The SATP groups were introduced in an attempt to deliver PFA after bioactivation inside the cells. The PFA prodrugs were evaluated in vitro for their activity against human immunodeficiency viruses (HIV-1 and HIV-2).

NOVEL VINBLASTINE DERIVATIVES, THEIR PREPARATION, USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAID DERIVATIVES

The invention provides vinblastine derivatives represented by the following formula 1 or their physiologically acceptable salts, their preparation, use and pharmaceutical compositions comprising the said derivatives. The said vinblastine derivatives show inhibiting activities against tumor cell lines and can be used as medicaments for treating malignant tumors.

Polyethylene glycol-based homologated ligands for nicotinic acetylcholine receptors

A homologous series of polyethylene glycol (PEG) monomethyl ethers were conjugated with three ligand series for nicotinic acetylcholine receptors. Conjugates of acetylaminocholine, the cyclic analog 1-acetyl-4,4-dimethylpiperazinium, and pyridyl ether A-84543 were prepared. Each series was found to retain significant affinity at nicotinic receptors in rat cerebral cortex with tethers of up to six PEG units. Such compounds are hydrophilic ligands which may serve as models for fluorescent/affinity probes and multivalent ligands for nAChR.

MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF

This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders.

Topical delivery of a model phenolic drug: Alkyloxycarbonyl prodrugs of acetaminophen

Purpose. To determine whether the delivery of a phenolic parent drug by its alkyloxycarbonyl (AOC) prodrugs through hairless mouse skin would show similar dependencies on water and lipid solubilities that similar prodrugs of more polar heterocyclic amide and imide parent drugs have shown. Methods. Flux through hairless mouse skin from suspensions in isopropyl myristate (JMIPM), solubilities in IPM (SIPM) and water (SAQ), and partition coefficients between isopropyl myristate (IPM) and pH 4.0 buffer (K IPM:4.0) were measured for two series of AOC derivatives of acetaminophen (APAP); their solubilities in pH 4.0 buffer (S4.0) were estimated from SIPM/KIPM: 4.0. Log JMIPM values were calculated from the n = 43 coefficients for the parameters in the transformed Potts-Guy (Roberts-Sloan) equation, and the average error of prediction (Δ log J′IPM) was calculated. The J MIPM, SIPM, S4.0, and molecular weight (MW) data for this series and two other series were combined with the n = 43 database to give a n = 61 database, and new best fit coefficients were determined for the Roberts-Sloan equation: log JMIPM = x + y log SIPM (1 - y) log S4.0 - z MW. Results. All of the 4-AOC-APAP derivatives underperformed based on their predicted log JMIPM (Δ log J′MIPM = 0.275 ± 0.147 log units) and, although the two more water soluble members of this more lipid soluble series were more effective than APAP, they were only marginally so: 2 = -0.322, 0.530, 0.00337 and 0.92, respectively. Conclusions. The topical delivery of a model phenolic drug by its AOC prodrugs through hairless mouse skin from IPM shows the same dependence on SIPM, S 4.0, and MW as the delivery of polar heterocycles by their similar prodrugs.

Functionalization of single-walled carbon nanotubes with (R-)oxycarbonyl nitrenes

Sidewall functionalization of single-walled carbon nanotubes (SWCNTs) via the addition of (R-)-oxycarbonyl nitrenes allows for the covalent binding of a variety of different groups such as alkyl chains, aromatic groups, dendrimers, crown ethers, and oligoethylene glycol units. Such additions lead to a considerable increase in the solubility in organic solvents such as 1,1,2,2-tetrachloroethane (TCE), dimethyl sulfoxide (DMSO), and 1,2-dichlorobenzene (ODCB). The highest solubilities of 1.2 mg/mL were found for SWCNT adducts with nitrenes containing crown ether of oligoethylene glycol moieties in DMSO and TCE, respectively. The presence of chelating donor groups within the addends allowed for the complexation of Cu2+ and Cd2+. Atomic force microscopy (AFM) and transmission electron microscopy (TEM) revealed that the functionalized tubes form thin bundles with typical diameters of 10 nm. The presence of thin bundles in solution is supported by 1H NMR spectroscopy. The elemental composition of the functionalized SWCNT was determined by X-ray photoelectron spectroscopy (XPS). The use of Raman and electron absorption spectroscopy (UV/Vis-nIR) showed that the electronic properties of the SWCNTs are mostly retained after functionalization, indicating a low degree of addition within this series of SWCNT derivatives.

Antiretroviral hydrazine derivatives

The invention relates to compounds of formula STR1 and salts, pharmaceutical compositions, intermediates and processes of preparation thereof.

Heat-sensitive recording materials and phenol compounds

Heat-sensitive recording materials contain an electron-donating chromogenic compound and an electron-attracting compound. The recording materials also contain at least one compound represented by the following formula: STR1 wherein R1 and R3 mean a hydrogen atom or an alkyl, aralkyl or aryl group, R2 and R4 denote an alkyl, alkenyl, aralkyl or aryl group, X1, X2, Y1 and Y2 stand for an oxygen or a sulfur atom, and --Z1 -- and --Z2 -- are a specific aromatic group. Also provided are phenol compounds represented by the following formula: STR2 wherein R1, R2, X1 and Y1 have the same meanings as defined above; R5 and R6 are a hydrogen or halogen atom or an alkyl, alkoxy, aralkyl, aryl or hydroxyl group; p and q stand for an integer of 1-4; R5 and R6 may be either the same or different when p and q represent an integer of 2 or greater; and --Z3 -- means a specific divalent group.

Novel carbonic acid esters

N- and/or O-acylates, derived from carbonic acid monoesters, of desferrioxamine B of the formula STR1 the symbols having the following meanings: each of AA1, AA2 and AA3, independently of the others, is hydrogen, an acyl radical, referred to as Ac, of a carboxylic acid having from 1 to 24 carbon atoms, or an esterified oxycarbonyl radical referred to as Cb (acyl radical of a carbonic acid monoester) having a total of from 2 to 25 carbon atoms, and B has one of the meanings of Cb or, if at least one of the symbols AA1, AA2 and AA3 represents Cb, it may also be hydrogen or an amino-protecting group referred to as X, form strong iron (III) and aluminum complexes within living cells and can therefore be used therapeutically for the treatment of warm-blooded animals, including humans, for pathological conditions associated with an excess of iron (III) or aluminum in the body or caused by iron (III)-dependent pathogenic organisms; they can also be used as intermediates for the manufacture of therapeutically effective derivatives of desferrioxamine B. The compounds according to the invention can be obtained by conventional acylation of the free amino group and/or hydroxy groups in desferrioxamine B or a suitable derivative thereof using a chloroformic ester or a similar reactive carbonic acid derivative.